用于肝细胞癌光热疗法和化疗协同作用的 "精准医疗 "纳米平台

IF 8.3 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

ACS Applied Materials & Interfaces Pub Date : 2024-09-18 DOI:10.1016/j.surfin.2024.105132

Xue-Jie Zhao , Lin-Song Li , Peng-Wei Chen , Dong Cheng , Bang-Bang Liu , Mei-Xia Zhao , Jianliang Shen

{"title":"用于肝细胞癌光热疗法和化疗协同作用的 \"精准医疗 \"纳米平台","authors":"Xue-Jie Zhao , Lin-Song Li , Peng-Wei Chen , Dong Cheng , Bang-Bang Liu , Mei-Xia Zhao , Jianliang Shen","doi":"10.1016/j.surfin.2024.105132","DOIUrl":null,"url":null,"abstract":"<div><div>Targeted peptide-mediated photothermal therapy (PTT) in combination with chemotherapy has great potency in the field of “precision medicine” because of its ability to increase drug enrichment in the focal region, reduce systemic toxicity, and provide the advantages of superb spatial-temporal control and non-invasiveness. In this work, we developed a FoxM1c-targeted nanoplatform (GSDP) for synergistic PTT and chemotherapy for hepatocellular carcinoma (HCC). Under irradiation with an 808-nm laser, the enriched nanodrug in tumor sites could convert near-infrared (NIR) light into heat, causing tumor temperature to exceed the safety threshold, the high temperature triggers the release of Doxorubicin (DOX) correspondingly, which can achiev the synergistic PTT-chemotherapy treatment. More strikingly, the nanoplatform achieved \"precision medicine\" of tumors due to the modification of 9R-P201 peptide, ultimately achieved a tumor suppression rate of 84.6% in HCC. Hence, the design of this synergistic therapeutic platform offers a new perspective for improving the therapeutic efficacy of HCC.</div></div>","PeriodicalId":5,"journal":{"name":"ACS Applied Materials & Interfaces","volume":null,"pages":null},"PeriodicalIF":8.3000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A “precision medicine” nanoplatform for synergistic photothermal therapy and chemotherapy in hepatocellular carcinoma\",\"authors\":\"Xue-Jie Zhao , Lin-Song Li , Peng-Wei Chen , Dong Cheng , Bang-Bang Liu , Mei-Xia Zhao , Jianliang Shen\",\"doi\":\"10.1016/j.surfin.2024.105132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Targeted peptide-mediated photothermal therapy (PTT) in combination with chemotherapy has great potency in the field of “precision medicine” because of its ability to increase drug enrichment in the focal region, reduce systemic toxicity, and provide the advantages of superb spatial-temporal control and non-invasiveness. In this work, we developed a FoxM1c-targeted nanoplatform (GSDP) for synergistic PTT and chemotherapy for hepatocellular carcinoma (HCC). Under irradiation with an 808-nm laser, the enriched nanodrug in tumor sites could convert near-infrared (NIR) light into heat, causing tumor temperature to exceed the safety threshold, the high temperature triggers the release of Doxorubicin (DOX) correspondingly, which can achiev the synergistic PTT-chemotherapy treatment. More strikingly, the nanoplatform achieved \\\"precision medicine\\\" of tumors due to the modification of 9R-P201 peptide, ultimately achieved a tumor suppression rate of 84.6% in HCC. Hence, the design of this synergistic therapeutic platform offers a new perspective for improving the therapeutic efficacy of HCC.</div></div>\",\"PeriodicalId\":5,\"journal\":{\"name\":\"ACS Applied Materials & Interfaces\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Materials & Interfaces\",\"FirstCategoryId\":\"88\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468023024012884\",\"RegionNum\":2,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MATERIALS SCIENCE, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Materials & Interfaces","FirstCategoryId":"88","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468023024012884","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

摘要

靶向肽介导的光热疗法（PTT）与化疗相结合，能够提高药物在病灶区域的富集度，降低全身毒性，并具有超强的时空控制和非侵入性等优点，在 "精准医疗 "领域具有巨大潜力。在这项工作中，我们开发了一种 FoxM1c 靶向纳米平台（GSDP），用于肝细胞癌（HCC）的协同 PTT 和化疗。在808纳米激光的照射下，肿瘤部位富集的纳米药物可将近红外光转化为热能，使肿瘤温度超过安全阈值，高温相应地引发多柔比星（DOX）的释放，从而实现PTT与化疗的协同治疗。更引人注目的是，由于 9R-P201 肽的修饰，该纳米平台实现了对肿瘤的 "精准医疗"，最终对 HCC 的抑瘤率达到 84.6%。因此，这一协同治疗平台的设计为提高 HCC 的疗效提供了新的视角。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A “precision medicine” nanoplatform for synergistic photothermal therapy and chemotherapy in hepatocellular carcinoma

查看原文本刊更多论文

A “precision medicine” nanoplatform for synergistic photothermal therapy and chemotherapy in hepatocellular carcinoma

Targeted peptide-mediated photothermal therapy (PTT) in combination with chemotherapy has great potency in the field of “precision medicine” because of its ability to increase drug enrichment in the focal region, reduce systemic toxicity, and provide the advantages of superb spatial-temporal control and non-invasiveness. In this work, we developed a FoxM1c-targeted nanoplatform (GSDP) for synergistic PTT and chemotherapy for hepatocellular carcinoma (HCC). Under irradiation with an 808-nm laser, the enriched nanodrug in tumor sites could convert near-infrared (NIR) light into heat, causing tumor temperature to exceed the safety threshold, the high temperature triggers the release of Doxorubicin (DOX) correspondingly, which can achiev the synergistic PTT-chemotherapy treatment. More strikingly, the nanoplatform achieved "precision medicine" of tumors due to the modification of 9R-P201 peptide, ultimately achieved a tumor suppression rate of 84.6% in HCC. Hence, the design of this synergistic therapeutic platform offers a new perspective for improving the therapeutic efficacy of HCC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Applied Materials & Interfaces 工程技术-材料科学：综合

CiteScore

16.00

自引率

6.30%

发文量

4978

审稿时长

1.8 months

期刊介绍： ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.